Filing identity and reporting period
The supplied filing is Diffusion Pharmaceuticals Inc.’s Form 10-K for the fiscal year ended December 31, 2018, filed March 19, 2019. It does not identify Cervomed Inc.; verify that this is the intended company and filing.
Diffusion is a clinical-stage biotechnology company with no product sales. Its lead candidate, TSC, is being developed for inoperable glioblastoma and acute stroke; RES-529 is an earlier-stage candidate. Financial comparisons below are for full-year 2018 versus full-year 2017, not Q4 alone.
Financial performance and liquidity
| Metric | 2018 | 2017 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $5.75 million | $5.09 million |
| General and administrative expense | $6.17 million | $6.19 million |
| Goodwill impairment | $6.93 million | None |
| Operating loss | $18.96 million | $11.35 million |
| Net loss | $18.37 million | $1.36 million |
| Cash used in operations | $10.77 million | $12.33 million |
| Cash and cash equivalents at year-end | $7.99 million | $8.90 million |
| Working capital at year-end | $8.11 million | $6.98 million |
| Debt at year-end | None | $0.55 million current convertible debt |
Gross margin is not meaningful because the company had no product revenue. Total assets were $18.20 million and stockholders’ equity was $15.61 million at year-end, down from $26.15 million and $21.23 million, respectively, in 2017. The company repaid approximately $0.6 million of Series B convertible notes and interest in 2018.
Material changes and unusual items
- Net loss rose substantially, principally reflecting the $6.93 million non-cash goodwill impairment and the absence of 2017’s large warrant-related accounting items. In 2017, a $22.07 million non-cash gain from warrant remeasurement partly offset $10.23 million of warrant-related expense and $2.87 million of other financing expenses; comparisons of net loss therefore are not indicative of operating trend alone.
- R&D expense increased about $0.66 million, including higher Phase 3 GBM trial costs, partly offset by lower manufacturing and other costs. G&A was broadly flat.
- The company raised approximately $10.8 million in a January 2018 common-stock-and-warrant offering. The Series A preferred stock converted into common stock, with shares also issued for accrued dividends and a make-whole adjustment. A 1-for-15 reverse stock split took effect in December 2018.
- Goodwill was written down to zero following declines in market capitalization; the separate RES-529 in-process R&D asset remained at $8.64 million and was not impaired.
Outlook, risks and contingencies
- Management estimated year-end cash would fund operations only into July 2019. It said additional capital, debt, or a partnering transaction would be needed to continue operations and complete the planned trials. The filing reports no committed external financing and substantial doubt about the company’s ability to continue as a going concern.
- The Phase 3 INTACT trial is planned for 236 patients with newly diagnosed inoperable GBM. Enrollment began in January 2018, but the company reported early enrollment challenges; it expected the eight-patient safety run-in to finish in Q2 2019 and did not anticipate trial results before 2024. Completion depends on financing, recruitment, and trial execution.
- The FDA permitted enrollment in the planned 160-patient Phase 2 PHAST-TSC acute-stroke study. Enrollment was expected in Q2 2019, subject to institutional review board and contracting activities, and the company also stated that additional liquidity would be needed to complete the trial.
- Management expected 2019 R&D expense to increase as the GBM and stroke trials proceeded. Other indications and further development of RES-529 were dependent on funding or potential partnering; the company was exploring out-licensing and other options.
- Key risks include clinical failure or delay, inability to raise capital, dilution or unfavorable partnering terms, regulatory hurdles, reliance on third-party manufacturers and research organizations, competition, and Nasdaq listing compliance. The filing says the company was in compliance with Nasdaq listing standards as of the report date after the reverse split.
- A former CEO’s claims were proceeding to arbitration, scheduled for November 2019. The company disputed the claims; the potential loss or range of loss was not estimable, and the filing says the matter could materially affect financial position depending on outcome.
- The independent auditor issued an unmodified opinion on the financial statements but highlighted substantial doubt about the company’s ability to continue as a going concern. Management reported effective internal control over financial reporting; the auditor did not attest to that assessment.
Most important facts to verify
- Confirm the intended issuer: the provided filing is for Diffusion Pharmaceuticals Inc., not Cervomed Inc.
- Check subsequent financing, cash runway, and whether the company continued as a going concern beyond the July 2019 estimate.
- Verify actual INTACT enrollment, safety-run-in outcome, trial timing, and any later results or protocol changes.
- Verify whether PHAST-TSC began enrollment and whether it obtained funding and required site approvals.
- Review later disclosures on the former CEO arbitration and any material change in the RES-529 asset’s status or valuation.
- Assess potential dilution from the 2.09 million warrants outstanding at year-end, alongside the common shares issued in the 2018 offering and preferred-stock conversion.